文献速递胸部技术与安全PETCT

新辅助免疫联合化疗治疗非小细胞肺癌的疗效评估:PET/CT与术后病理的比较

Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
PubMed 文献 · Eur Radiol · 2023-07-29

回顾性分析67例可切除II/IIIA期非小细胞肺癌患者新辅助免疫联合化疗前后的PET/CT代谢参数与CT大小,比较基于(i)RECIST的CT评估与基于PERCIST的PET/CT评估,并分析其与术后病理的相关性。PET/CT评估与术后病理评估一致性高,而CT评估一致性低;(i)RECIST与PERCIST标准差异有统计学意义(p < 0.001);术后病理反应与ΔSUVmax(%)(r = -0.812,p < 0.001)、ΔSUVmean(%)(r = -0.805,p < 0.001)及ΔSUVpeak(%)(r = -0.800,p < 0.001)呈负相关。

要点

  • PERCIST标准较(i)RECIST标准更敏感、更准确,能识别更多新辅助免疫联合化疗的应答者。
  • ΔSUVmax(%)、ΔSUVmean(%)、ΔSUVpeak(%)与术后病理反应强相关,cut-off值分别为75.8、67.8、74.6。
  • PET/CT评估与术后病理评估一致性高,而CT评估一致性低。

核心结论

  • PERCIST标准较(i)RECIST标准更敏感、更准确,能识别更多新辅助免疫联合化疗的NSCLC应答者;PET/CT在预测术后病理反应方面准确性高,在疗效评估、预测预后及指导术后治疗中起重要作用。

研究设计与样本

  • 回顾性分析67例可切除II/IIIA期非小细胞肺癌患者新辅助免疫联合化疗前后的PET/CT代谢参数与CT大小,比较基于(i)RECIST的CT评估与基于PERCIST的PET/CT评估,并分析PET/CT代谢参数与术后病理的相关性。

诊断标准与关键数值

  • PET/CT评估与术后病理评估一致性高,CT评估与术后病理评估一致性低;(i)RECIST与PERCIST标准差异有统计学意义(p < 0.001);术后病理反应与ΔSUVmax(%)(r = -0.812,p < 0.001)、ΔSUVmean(%)(r = -0.805,p < 0.001)、ΔSUVpeak(%)(r = -0.800,p < 0.001)呈负相关;ΔSUVmax(%) cut-off值75.8、ΔSUVmean(%) cut-off值67.8、ΔSUVpeak(%) cut-off值74.6具有最高敏感度和特异度。

临床应用与阅片要点

  • 在新辅助免疫联合化疗后的疗效评估中,PERCIST标准较(i)RECIST标准更敏感、更准确,能识别更多应答者;PET/CT代谢参数ΔSUVmax(%)、ΔSUVmean(%)、ΔSUVpeak(%)与术后病理反应强相关,可用于预测术后病理反应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the value of positron emission tomography/computed tomography (PET/CT) in the efficacy evaluation of patients undergoing neoadjuvant immunotherapy plus chemotherapy, and to analyze its correlation with postoperative pathology.

METHODS: The PET/CT metabolic parameters and CT size were retrospectively analyzed before and after neoadjuvant immunotherapy plus chemotherapy in 67 patients with resectable stage II/IIIA non-small-cell lung cancer (NSCLC). CT assessment based on immune response evaluation criteria in solid tumor criteria ((i)RECIST) was compared with PET/CT assessment based on the response criteria in solid tumors (PERCIST). The correlations between PET/CT metabolic parameters and postoperative pathology were analyzed. The value of PET/CT in the efficacy evaluation was assessed.

RESULTS: The PET/CT assessment showed high consistency with postoperative pathological evaluation, yet the CT assessment showed low consistency with postoperative pathological evaluation. The (i)RECIST and PERCIST criteria showed statistically significant differences (p < 0.001). The postoperative pathological response was negatively associated with ΔSUVmax (%) (r = - 0.812, p < 0.001), ΔSUVmean (%) (r = - 0.805, p < 0.001), and ΔSUVpeak (%) (r = - 0.800, p < 0.001). The cut-off values of 75.8 for ΔSUVmax (%), 67.8 for ΔSUVmean (%), and 74.6 for ΔSUVpeak (%) had the highest sensitivity and specificity.

CONCLUSION: The PERCIST criteria are more sensitive and accurate than (i)RECIST criteria to identify more responders when evaluating the response of neoadjuvant immunotherapy plus chemotherapy for NSCLC. PET/CT shows high accuracy in predicting postoperative pathological response. Our study shows the important role PET/CT plays in the efficacy evaluation of NSCLC patients undergoing neoadjuvant immunotherapy plus chemotherapy, as well as in predicting the prognosis and guiding postoperative treatment.

CLINICAL RELEVANCE STATEMENT: Neoadjuvant immunotherapy plus chemotherapy is highly effective in the treatment of non-small-cell lung cancer. And PET/CT played an important role in the efficacy evaluation following neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer.

KEY POINTS: • Neoadjuvant immunotherapy plus chemotherapy is highly effective in the treatment of NSCLC. • The PERCIST criteria are more sensitive and accurate than (i)RECIST criteria to identify more responders when evaluating the response of neoadjuvant immunotherapy plus chemotherapy for NSCLC. • PET/CT played an important role in the efficacy evaluation; ΔSUVmax (%), ΔSUVmean (%), and ΔSUVpeak (%) following neoadjuvant immunotherapy plus chemotherapy for NSCLC had high consistency and strong correlations with postoperative pathology.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Cheng Y, Chen ZY, Huang JJ, et al. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology. Eur Radiol. 2023. PMID: 37515634. doi:10.1007/s00330-023-09922-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。